Literature DB >> 19813044

Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption.

M Matsubara1, E Yamachika, H Tsujigiwa, N Mizukawa, T Ueno, J Murakami, N Ishida, Y Kaneda, N Shirasu, S Takagi.   

Abstract

SUMMARY: The main component of the metabolic by-products of fermentation by Propionibacterium freudenreichii ET-3 is 1,4-dihydroxy-2-naphthoic acid (DHNA), which has a naphthoquinone skeleton, as in vitamin K2. This study showed that DHNA improved bone mass reduction with osteoporosis model mice caused by FK506.
INTRODUCTION: Growth of the intestinal bacterium Lactobacillus bifidus is specifically facilitated by DHNA. The present study used osteoporosis model mice to investigate the effects of DHNA on bone remodeling.
METHODS: FK506, an immunosuppressant, was used to prepare osteoporosis model mice. Thirty mice were divided into three groups: FK group, FK+DHNA group, and control group. In the FK group, FK506 was administered to induce bone mass reduction. In the FK-DHNA group, FK506 and DHNA were administered concurrently to observe improvements in bone mass reduction. To ascertain systemic and local effects of DHNA, we investigated systemic pathological changes in colon, kidney function and cytokine dynamics, and morphological and organic changes in bone and osteoclast dynamics as assessed by culture experiments.
RESULTS: Compared to the FK group without DHNA, colon damage and kidney dysfunction were milder for FK+DHNA group, and production of inflammatory cytokines (interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha) was more suppressed. Furthermore, compared to the group without DHNA, histological analyses and radiography showed that bone resorption was suppressed for the DHNA group. Culture experiments using osteoclasts from murine bone marrow showed osteoclast suppression for the DHNA group compared to the group without DHNA.
CONCLUSION: These results show that DHNA has some effects for improving bone mass reduction caused by FK506.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19813044     DOI: 10.1007/s00198-009-1075-y

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  37 in total

1.  Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics.

Authors:  A Monegal; M Navasa; N Guañabens; P Peris; F Pons; M J Martinez de Osaba; J Ordi; A Rimola; J Rodés; J Muñoz-Gómez
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

Review 2.  FK 506: historical perspectives.

Authors:  T Goto; T Kino; H Hatanaka; M Okuhara; M Kohsaka; H Aoki; H Imanaka
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models.

Authors:  J R Green; Y Seltenmeyer; K A Jaeggi; L Widler
Journal:  Pharmacol Toxicol       Date:  1997-05

Review 4.  [Avoiding emergency situations under anticoagulant therapy with vitamin K antagonists].

Authors:  C E Dempfle; M Borggrefe
Journal:  Internist (Berl)       Date:  2005-09       Impact factor: 0.743

5.  Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts.

Authors:  Y Azuma; K Kaji; R Katogi; S Takeshita; A Kudo
Journal:  J Biol Chem       Date:  2000-02-18       Impact factor: 5.157

6.  Regulation of bone metabolism in immunosuppressant (FK506)-treated rats.

Authors:  Shiho Kirino; Jyoji Fukunaga; Shuji Ikegami; Hiroshi Tsuboi; Masataka Kimata; Naoki Nakata; Makoto Nakano; Takaaki Ueno; Nobuyoshi Mizukawa; Toshio Sugahara
Journal:  J Bone Miner Metab       Date:  2004       Impact factor: 2.626

7.  A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group.

Authors:  J D Pirsch; J Miller; M H Deierhoi; F Vincenti; R S Filo
Journal:  Transplantation       Date:  1997-04-15       Impact factor: 4.939

Review 8.  Osteoporosis after organ transplantation.

Authors:  M A Rodino; E Shane
Journal:  Am J Med       Date:  1998-05       Impact factor: 4.965

9.  Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis.

Authors:  C M Gordon; E Binello; M S LeBoff; M E Wohl; C J Rosen; A A Colin
Journal:  Osteoporos Int       Date:  2006-03-16       Impact factor: 4.507

10.  Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.

Authors:  K Kobayashi; N Takahashi; E Jimi; N Udagawa; M Takami; S Kotake; N Nakagawa; M Kinosaki; K Yamaguchi; N Shima; H Yasuda; T Morinaga; K Higashio; T J Martin; T Suda
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  4 in total

1.  Methyl-1-hydroxy-2-naphthoate, a novel naphthol derivative, inhibits lipopolysaccharide-induced inflammatory response in macrophages via suppression of NF-κB, JNK and p38 MAPK pathways.

Authors:  Jun-Yan Zhang; Hong Jin; Guang-Fa Wang; Peng-Jiu Yu; Shao-Yu Wu; Zheng-Guang Zhu; Zhong-Huang Li; Yuan-Xin Tian; Wei Xu; Jia-Jie Zhang; Shu-Guang Wu
Journal:  Inflamm Res       Date:  2011-06-11       Impact factor: 4.575

2.  Lactobacillus fermentation enhances the inhibitory effect of Hwangryun-haedok-tang in an ovariectomy-induced bone loss.

Authors:  Ki-Shuk Shim; Taesoo Kim; Hyunil Ha; Kwang Jin Lee; Chang-Won Cho; Han Sung Kim; Dong-Hyun Seo; Jin Yeul Ma
Journal:  BMC Complement Altern Med       Date:  2013-05-16       Impact factor: 3.659

3.  Hwangryun-Haedok-Tang Fermented with Lactobacillus casei Suppresses Ovariectomy-Induced Bone Loss.

Authors:  Ki-Shuk Shim; Taesoo Kim; Hyunil Ha; Chang-Won Cho; Han Sung Kim; Dong-Hyun Seo; Jin Yeul Ma
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-02       Impact factor: 2.629

4.  Detection of 1,4-dihydroxy-2-naphthoic Acid from commercial makgeolli products.

Authors:  Ji-Eun Eom; Sang-Chul Kwon; Gi-Seong Moon
Journal:  Prev Nutr Food Sci       Date:  2012-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.